SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
